

G Michael Felker

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5234545/publications.pdf>

Version: 2024-02-01

410
papers

35,411
citations

3158

92
h-index

4014

176
g-index

439
all docs

439
docs citations

439
times ranked

23874
citing authors

#	ARTICLE	IF	CITATIONS
1	Underlying Causes and Long-Term Survival in Patients with Initially Unexplained Cardiomyopathy. <i>New England Journal of Medicine</i> , 2000, 342, 1077-1084.	27.0	1,464
2	Diuretic Strategies in Patients with Acute Decompensated Heart Failure. <i>New England Journal of Medicine</i> , 2011, 364, 797-805.	27.0	1,363
3	Effect of Nesiritide in Patients with Acute Decompensated Heart Failure. <i>New England Journal of Medicine</i> , 2011, 365, 32-43.	27.0	1,133
4	Effect of Phosphodiesterase-5 Inhibition on Exercise Capacity and Clinical Status in Heart Failure With Preserved Ejection Fraction. <i>JAMA - Journal of the American Medical Association</i> , 2013, 309, 1268.	7.4	976
5	Serelaxin, recombinant human relaxin-2, for treatment of acute heart failure (RELAX-AHF): a randomised, placebo-controlled trial. <i>Lancet</i> , The, 2013, 381, 29-39.	13.7	810
6	Red Cell Distribution Width as a Novel Prognostic Marker in Heart Failure. <i>Journal of the American College of Cardiology</i> , 2007, 50, 40-47.	2.8	809
7	Ultrafiltration in Decompensated Heart Failure with Cardiorenal Syndrome. <i>New England Journal of Medicine</i> , 2012, 367, 2296-2304.	27.0	790
8	Decision Making in Advanced Heart Failure. <i>Circulation</i> , 2012, 125, 1928-1952.	1.6	678
9	Universal definition and classification of heart failure: a report of the Heart Failure Society of America, Heart Failure Association of the European Society of Cardiology, Japanese Heart Failure Society and Writing Committee of the Universal Definition of Heart Failure. <i>European Journal of Heart Failure</i> , 2021, 23, 352-380.	7.1	630
10	Relation of frequency and severity of mitral regurgitation to survival among patients with left ventricular systolic dysfunction and heart failure. <i>American Journal of Cardiology</i> , 2003, 91, 538-543.	1.6	623
11	A standardized definition of ischemic cardiomyopathy for use in clinical research. <i>Journal of the American College of Cardiology</i> , 2002, 39, 210-218.	2.8	537
12	Heart failure etiology and response to milrinone in decompensated heart failure. <i>Journal of the American College of Cardiology</i> , 2003, 41, 997-1003.	2.8	490
13	Effects of Liraglutide on Clinical Stability Among Patients With Advanced Heart Failure and Reduced Ejection Fraction. <i>JAMA - Journal of the American Medical Association</i> , 2016, 316, 500.	7.4	457
14	Isosorbide Mononitrate in Heart Failure with Preserved Ejection Fraction. <i>New England Journal of Medicine</i> , 2015, 373, 2314-2324.	27.0	453
15	Lower Serum Sodium Is Associated With Increased Short-Term Mortality in Hospitalized Patients With Worsening Heart Failure. <i>Circulation</i> , 2005, 111, 2454-2460.	1.6	449
16	Role of Biomarkers for the Prevention, Assessment, and Management of Heart Failure: A Scientific Statement From the American Heart Association. <i>Circulation</i> , 2017, 135, e1054-e1091.	1.6	417
17	Low-Dose Dopamine or Low-Dose Nesiritide in Acute Heart Failure With Renal Dysfunction. <i>JAMA - Journal of the American Medical Association</i> , 2013, 310, 2533.	7.4	410
18	Association of Change in N-Terminal Pro-B-Type Natriuretic Peptide Following Initiation of Sacubitril-Valsartan Treatment With Cardiac Structure and Function in Patients With Heart Failure With Reduced Ejection Fraction. <i>JAMA - Journal of the American Medical Association</i> , 2019, 322, 1085.	7.4	403

#	ARTICLE	IF	CITATIONS
19	Effect of Serelaxin on Cardiac, Renal, and Hepatic Biomarkers in the Relaxin in Acute Heart Failure (RELAX-AHF) Development Program. <i>Journal of the American College of Cardiology</i> , 2013, 61, 196-206.	2.8	397
20	Relaxin for the treatment of patients with acute heart failure (Pre-RELAX-AHF): a multicentre, randomised, placebo-controlled, parallel-group, dose-finding phase IIb study. <i>Lancet</i> , The, 2009, 373, 1429-1439.	13.7	387
21	Effect of Natriuretic Peptide-Guided Therapy on Hospitalization or Cardiovascular Mortality in High-Risk Patients With Heart Failure and Reduced Ejection Fraction. <i>JAMA - Journal of the American Medical Association</i> , 2017, 318, 713.	7.4	386
22	Cardiac Myosin Activation with Omecamtiv Mecarbil in Systolic Heart Failure. <i>New England Journal of Medicine</i> , 2021, 384, 105-116.	27.0	381
23	Calcium upregulation by percutaneous administration of gene therapy in patients with cardiac disease (CUPID 2): a randomised, multinational, double-blind, placebo-controlled, phase 2b trial. <i>Lancet</i> , The, 2016, 387, 1178-1186.	13.7	373
24	Troponin Elevation in Heart Failure. <i>Journal of the American College of Cardiology</i> , 2010, 56, 1071-1078.	2.8	371
25	Universal Definition and Classification of Heart Failure. <i>Journal of Cardiac Failure</i> , 2021, 27, 387-413.	1.7	362
26	Echocardiographic findings in fulminant and acute myocarditis. <i>Journal of the American College of Cardiology</i> , 2000, 36, 227-232.	2.8	351
27	Validation and Potential Mechanisms of Red Cell Distribution Width as a Prognostic Marker in Heart Failure. <i>Journal of Cardiac Failure</i> , 2010, 16, 230-238.	1.7	344
28	Effect of Oral Iron Repletion on Exercise Capacity in Patients With Heart Failure With Reduced Ejection Fraction and Iron Deficiency. <i>JAMA - Journal of the American Medical Association</i> , 2017, 317, 1958.	7.4	329
29	Liver function abnormalities and outcome in patients with chronic heart failure: data from the Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity (CHARM) program. <i>European Journal of Heart Failure</i> , 2009, 11, 170-177.	7.1	326
30	Biomarker-guided therapy in chronic heart failure: A meta-analysis of randomized controlled trials. <i>American Heart Journal</i> , 2009, 158, 422-430.	2.7	303
31	Risk stratification after hospitalization for decompensated heart failure. <i>Journal of Cardiac Failure</i> , 2004, 10, 460-466.	1.7	291
32	Loop Diuretics in Acute Decompensated Heart Failure. <i>Circulation: Heart Failure</i> , 2009, 2, 56-62.	3.9	258
33	Cardiohepatic Interactions in Heart Failure. <i>Journal of the American College of Cardiology</i> , 2013, 61, 2397-2405.	2.8	240
34	Mechanisms of Bleeding and Approach to Patients With Axial-Flow Left Ventricular Assist Devices. <i>Circulation: Heart Failure</i> , 2011, 4, 779-784.	3.9	239
35	Effects of Xanthine Oxidase Inhibition in Hyperuricemic Heart Failure Patients. <i>Circulation</i> , 2015, 131, 1763-1771.	1.6	239
36	Worsening Renal Function in Patients With Acute Heart Failure Undergoing Aggressive Diuresis Is Not Associated With Tubular Injury. <i>Circulation</i> , 2018, 137, 2016-2028.	1.6	239

#	ARTICLE	IF	CITATIONS
37	Relief and Recurrence of Congestion During and After Hospitalization for Acute Heart Failure. <i>Circulation: Heart Failure</i> , 2015, 8, 741-748.	3.9	235
38	Discordance Between Patient-Predicted and Model-Predicted Life Expectancy Among Ambulatory Patients With Heart Failure. <i>JAMA - Journal of the American Medical Association</i> , 2008, 299, 2533.	7.4	233
39	Diuretic Treatment in Heart Failure. <i>New England Journal of Medicine</i> , 2017, 377, 1964-1975.	27.0	232
40	Anemia as a risk factor and therapeutic target in heart failure. <i>Journal of the American College of Cardiology</i> , 2004, 44, 959-966.	2.8	231
41	Chronic Oral Study of Myosin Activation to Increase Contractility in Heart Failure (COSMIC-HF): a phase 2, pharmacokinetic, randomised, placebo-controlled trial. <i>Lancet, The</i> , 2016, 388, 2895-2903.	13.7	229
42	Red blood cell distribution width and 1-year mortality in acute heart failure. <i>European Journal of Heart Failure</i> , 2010, 12, 129-136.	7.1	224
43	Inotropic therapy for heart failure: An evidence-based approach. <i>American Heart Journal</i> , 2001, 142, 393-401.	2.7	223
44	Improving care for patients with acute heart failure: before, during and after hospitalization. <i>ESC Heart Failure</i> , 2014, 1, 110-145.	3.1	222
45	Galectin-3 in Ambulatory Patients With Heart Failure. <i>Circulation: Heart Failure</i> , 2012, 5, 72-78.	3.9	211
46	The Spectrum of Dilated Cardiomyopathy: The Johns Hopkins Experience with 1,278 Patients. <i>Medicine (United States)</i> , 1999, 78, 270-283.	1.0	206
47	Usefulness of anemia as a predictor of death and rehospitalization in patients with decompensated heart failure. <i>American Journal of Cardiology</i> , 2003, 92, 625-628.	1.6	200
48	Admission, Discharge, or Change in B-Type Natriuretic Peptide and Long-Term Outcomes. <i>Circulation: Heart Failure</i> , 2011, 4, 628-636.	3.9	199
49	Efficacy and Safety of Spironolactone in Acute Heart Failure. <i>JAMA Cardiology</i> , 2017, 2, 950.	6.1	199
50	Clinical Implications of Chronic Heart Failure Phenotypes Defined by Cluster Analysis. <i>Journal of the American College of Cardiology</i> , 2014, 64, 1765-1774.	2.8	197
51	Acute Treatment With Omecamtiv Mecarbil to Increase Contractility in Acute Heart Failure. <i>Journal of the American College of Cardiology</i> , 2016, 67, 1444-1455.	2.8	191
52	Effect of Inorganic Nitrite vs Placebo on Exercise Capacity Among Patients With Heart Failure With Preserved Ejection Fraction. <i>JAMA - Journal of the American Medical Association</i> , 2018, 320, 1764.	7.4	187
53	The pathophysiology of acute heart failure—Is it all about fluid accumulation?. <i>American Heart Journal</i> , 2008, 155, 9-18.	2.7	179
54	Metabolomic Profiling Identifies Novel Circulating Biomarkers of Mitochondrial Dysfunction Differentially Elevated in Heart Failure With Preserved Versus Reduced Ejection Fraction: Evidence for Shared Metabolic Impairments in Clinical Heart Failure. <i>Journal of the American Heart Association</i> , 2016, 5, .	3.7	178

#	ARTICLE	IF	CITATIONS
55	Effects of Serelaxin in Patients with Acute Heart Failure. <i>New England Journal of Medicine</i> , 2019, 381, 716-726.	27.0	174
56	Efficacy and Safety of Tolvaptan in Patients Hospitalized With Acute Heart Failure. <i>Journal of the American College of Cardiology</i> , 2017, 69, 1399-1406.	2.8	171
57	The problem of decompensated heart failure: Nomenclature, classification, and risk stratification. <i>American Heart Journal</i> , 2003, 145, S18-S25.	2.7	159
58	Natriuretic peptide-guided heart failure management. <i>European Heart Journal</i> , 2014, 35, 16-24.	2.2	159
59	Diuretic Therapy for Patients With Heart Failure. <i>Journal of the American College of Cardiology</i> , 2020, 75, 1178-1195.	2.8	159
60	Myocarditis and long-term survival in peripartum cardiomyopathy. <i>American Heart Journal</i> , 2000, 140, 785-791.	2.7	158
61	Machine Learning Methods Improve Prognostication, Identify Clinically Distinct Phenotypes, and Detect Heterogeneity in Response to Therapy in a Large Cohort of Heart Failure Patients. <i>Journal of the American Heart Association</i> , 2018, 7, .	3.7	153
62	The Diastolic Pulmonary Gradient Does Not Predict Survival in Patients With Pulmonary Hypertension Due to Left Heart Disease. <i>JACC: Heart Failure</i> , 2015, 3, 9-16.	4.1	151
63	Markers of Decongestion, Dyspnea Relief, and Clinical Outcomes Among Patients Hospitalized With Acute Heart Failure. <i>Circulation: Heart Failure</i> , 2013, 6, 240-245.	3.9	147
64	Prognostic Implications of Long-Chain Acylcarnitines in Heart Failure and Reversibility With Mechanical Circulatory Support. <i>Journal of the American College of Cardiology</i> , 2016, 67, 291-299.	2.8	143
65	Diuretics and Ultrafiltration in Acute Decompensated Heart Failure. <i>Journal of the American College of Cardiology</i> , 2012, 59, 2145-2153.	2.8	142
66	Clinical Trials of Pharmacological Therapies in Acute Heart Failure Syndromes. <i>Circulation: Heart Failure</i> , 2010, 3, 314-325.	3.9	134
67	2013 ACCF/ACR/ASE/ASNC/SCCT/SCMR Appropriate Utilization of Cardiovascular Imaging in Heart Failure. <i>Journal of the American College of Cardiology</i> , 2013, 61, 2207-2231.	2.8	134
68	Diuretic response in patients with acute decompensated heart failure: characteristics and clinical outcome—an analysis from RELAX-AHF. <i>European Journal of Heart Failure</i> , 2014, 16, 1230-1240.	7.1	134
69	Trends in Noncardiovascular Comorbidities Among Patients Hospitalized for Heart Failure. <i>Circulation: Heart Failure</i> , 2018, 11, e004646.	3.9	134
70	Clinical Implications of the New York Heart Association Classification. <i>Journal of the American Heart Association</i> , 2019, 8, e014240.	3.7	133
71	Pulmonary Hypertension and Risk of Death in Cardiomyopathy. <i>Circulation</i> , 2002, 105, 1663-1668.	1.6	130
72	Role of Volume Redistribution in the Congestion of Heart Failure. <i>Journal of the American Heart Association</i> , 2017, 6, .	3.7	128

#	ARTICLE	IF	CITATIONS
73	Design of a Phase 2b Trial of Intracoronary Administration of AAV1/SERCA2a in Patients With Advanced Heart Failure. <i>JACC: Heart Failure</i> , 2014, 2, 84-92.	4.1	123
74	Hemodynamic Predictors of Heart Failure Morbidity and Mortality: Fluid or Flow?. <i>Journal of Cardiac Failure</i> , 2016, 22, 182-189.	1.7	118
75	Inotropes in the management of acute heart failure. <i>Critical Care Medicine</i> , 2008, 36, S106-S111.	0.9	117
76	Marginal Cardiac Allografts Do Not Have Increased Primary Graft Dysfunction in Alternate List Transplantation. <i>Circulation</i> , 2006, 114, I-27-I-32.	1.6	116
77	Soluble ST2 in Ambulatory Patients With Heart Failure. <i>Circulation: Heart Failure</i> , 2013, 6, 1172-1179.	3.9	114
78	Relaxin, a pleiotropic vasodilator for the treatment of heart failure. <i>Heart Failure Reviews</i> , 2009, 14, 321-329.	3.9	113
79	Decongestion in acute heart failure. <i>European Journal of Heart Failure</i> , 2014, 16, 471-482.	7.1	113
80	Serial high sensitivity cardiac troponin T measurement in acute heart failure: insights from the RELAX-AHF study. <i>European Journal of Heart Failure</i> , 2015, 17, 1262-1270.	7.1	110
81	Novel biomarkers in chronic heart failure. <i>Nature Reviews Cardiology</i> , 2012, 9, 347-359.	13.7	108
82	Coenzyme Q10 and Heart Failure. <i>Circulation: Heart Failure</i> , 2016, 9, e002639.	3.9	108
83	Rationale and Design of the GUIDE-IT Study. <i>JACC: Heart Failure</i> , 2014, 2, 457-465.	4.1	106
84	Biomarkers of Myocardial Stress and Fibrosis as Predictors of Mode of Death in Patients With Chronic Heart Failure. <i>JACC: Heart Failure</i> , 2014, 2, 260-268.	4.1	104
85	Serelaxin in addition to standard therapy in acute heart failure: rationale and design of the RELAX-AHF study. <i>European Journal of Heart Failure</i> , 2017, 19, 800-809.	7.1	104
86	Heart Failure With Preserved Ejection Fraction Expert Panel Report. <i>JACC: Heart Failure</i> , 2018, 6, 619-632.	4.1	103
87	Current Evidence on Treatment of Patients With Chronic Systolic Heart Failure and Renal Insufficiency. <i>Journal of the American College of Cardiology</i> , 2014, 63, 853-871.	2.8	102
88	Biased ligand of the angiotensin II type 1 receptor in patients with acute heart failure: a randomized, double-blind, placebo-controlled, phase IIB, dose ranging trial (BLAST-AHF). <i>European Heart Journal</i> , 2017, 38, 2364-2373.	2.2	102
89	Troponin I in acute decompensated heart failure: insights from the ASCEND-HF study. <i>European Journal of Heart Failure</i> , 2012, 14, 1257-1264.	7.1	101
90	Omecamtiv Mecarbil in Chronic Heart Failure With Reduced Ejection Fraction. <i>JACC: Heart Failure</i> , 2020, 8, 329-340.	4.1	100

#	ARTICLE	IF	CITATIONS
91	Early drop in systolic blood pressure and worsening renal function in acute heart failure: renal results of Preâ€RELAXâ€AHF. <i>European Journal of Heart Failure</i> , 2011, 13, 961-967.	7.1	99
92	Decongestion Strategies and Renin-Angiotensin-Aldosterone System Activation in Acute Heart Failure. <i>JACC: Heart Failure</i> , 2015, 3, 97-107.	4.1	95
93	End Points for Clinical Trials in Acute Heart Failure Syndromes. <i>Journal of the American College of Cardiology</i> , 2009, 53, 2248-2258.	2.8	92
94	Natriuretic peptides in the diagnosis and management of heart failure. <i>Cmaj</i> , 2006, 175, 611-617.	2.0	91
95	Cardiorenal Rescue Study in Acute Decompensated Heart Failure: Rationale and Design of CARRESS-HF, for the Heart Failure Clinical Research Network. <i>Journal of Cardiac Failure</i> , 2012, 18, 176-182.	1.7	91
96	Recurrence of Cardiac Sarcoidosis in a Heart Transplant Recipient. <i>Journal of Heart and Lung Transplantation</i> , 2005, 24, 1988-1990.	0.6	90
97	Serelaxin in acute heart failure patients with preserved left ventricular ejection fraction: results from the RELAX-AHF trial. <i>European Heart Journal</i> , 2014, 35, 1041-1050.	2.2	90
98	Outpatient Worsening Heart Failure as a Target for Therapy. <i>JAMA Cardiology</i> , 2018, 3, 252.	6.1	90
99	Enhancement of Nitrosourea Activity in Medulloblastoma and Glioblastoma Multiforme. <i>Journal of the National Cancer Institute</i> , 1992, 84, 1926-1931.	6.3	89
100	Dyspnoea and worsening heart failure in patients with acute heart failure: results from the Preâ€RELAXâ€AHF study. <i>European Journal of Heart Failure</i> , 2010, 12, 1130-1139.	7.1	88
101	Anemia in patients with heart failure and preserved systolic function. <i>American Heart Journal</i> , 2006, 151, 457-462.	2.7	87
102	Growth differentiation factor 15 (<sc>GDF</sc>â€15) in patients admitted for acute heart failure: results from the <sc>RELAXâ€AHF</sc> study. <i>European Journal of Heart Failure</i> , 2015, 17, 1133-1143.	7.1	86
103	B-Type Natriuretic Peptide â€” A Biomarker for All Seasons?. <i>New England Journal of Medicine</i> , 2004, 350, 718-720.	27.0	85
104	Body Weight Change During and After Hospitalization for Acute Heart Failure: Patient Characteristics, Markers of Congestion, and Outcomes. <i>JACC: Heart Failure</i> , 2017, 5, 1-13.	4.1	84
105	Charting a Roadmap for Heart Failure Biomarker Studies. <i>JACC: Heart Failure</i> , 2014, 2, 477-488.	4.1	81
106	A multimarker multi-time point-based risk stratification strategy in acute heart failure: results from the <sc>RELAXâ€AHF</sc> trial. <i>European Journal of Heart Failure</i> , 2017, 19, 1001-1010.	7.1	81
107	Prevalence of AAV1 neutralizing antibodies and consequences for a clinical trial of gene transfer for advanced heart failure. <i>Gene Therapy</i> , 2016, 23, 313-319.	4.5	79
108	Outcomes With an Alternate List Strategy for Heart Transplantation. <i>Journal of Heart and Lung Transplantation</i> , 2005, 24, 1781-1786.	0.6	75

#	ARTICLE	IF	CITATIONS
109	Assessment of Limitations to Optimization of Guideline-Directed Medical Therapy in Heart Failure From the GUIDE-IT Trial. <i>JAMA Cardiology</i> , 2020, 5, 757.	6.1	74
110	Early Management of Patients With Acute Heart Failure: State of the Art and Future Directions. A Consensus Document From the Society for Academic Emergency Medicine/Heart Failure Society of America Acute Heart Failure Working Group. <i>Journal of Cardiac Failure</i> , 2015, 21, 27-43.	1.7	73
111	Effect of Ejection Fraction on Clinical Outcomes in Patients Treated With Omecamtiv Mecarbil in GALACTIC-HF. <i>Journal of the American College of Cardiology</i> , 2021, 78, 97-108.	2.8	73
112	The Valsalva Maneuver: A Bedside “Biomarker” for Heart Failure. <i>American Journal of Medicine</i> , 2006, 119, 117-122.	1.5	72
113	Inflammatory Biomarkers in Heart Failure. <i>Congestive Heart Failure</i> , 2006, 12, 324-328.	2.0	71
114	Effects of Left Ventricular Assist Device Support on Biomarkers of Cardiovascular Stress, Fibrosis, Fluid Homeostasis, Inflammation, and Renal Injury. <i>JACC: Heart Failure</i> , 2015, 3, 30-39.	4.1	70
115	Utility of Growth Differentiation Factor-15, A Marker of Oxidative Stress and Inflammation, in Chronic Heart Failure. <i>JACC: Heart Failure</i> , 2017, 5, 724-734.	4.1	69
116	Regional adiposity and heart failure with preserved ejection fraction. <i>European Journal of Heart Failure</i> , 2020, 22, 1540-1550.	7.1	69
117	Patient- and Trial-Specific Barriers to Participation in Cardiovascular Randomized Clinical Trials. <i>Journal of the American College of Cardiology</i> , 2013, 61, 762-769.	2.8	68
118	Heart Failure Therapeutics on the Basis of a Biased Ligand of the Angiotensin-2 Type 1 Receptor. <i>JACC: Heart Failure</i> , 2015, 3, 193-201.	4.1	68
119	Relaxin-2 and Soluble Flt1 Levels in Peripartum Cardiomyopathy. <i>JACC: Heart Failure</i> , 2016, 4, 380-388.	4.1	68
120	Rhythm Control Versus Rate Control in Patients With Atrial Fibrillation and Heart Failure With Preserved Ejection Fraction: Insights From Get With The Guidelines Heart Failure. <i>Journal of the American Heart Association</i> , 2019, 8, e011560.	3.7	68
121	Effect of a Hospital and Postdischarge Quality Improvement Intervention on Clinical Outcomes and Quality of Care for Patients With Heart Failure With Reduced Ejection Fraction. <i>JAMA - Journal of the American Medical Association</i> , 2021, 326, 314.	7.4	68
122	Clinical outcomes in patients on beta-blocker therapy admitted with worsening chronic heart failure. <i>American Journal of Cardiology</i> , 2003, 91, 169-174.	1.6	67
123	A Global Rank End Point for Clinical Trials in Acute Heart Failure. <i>Circulation: Heart Failure</i> , 2010, 3, 643-646.	3.9	66
124	Association of Novel Biomarkers of Cardiovascular Stress With Left Ventricular Hypertrophy and Dysfunction: Implications for Screening. <i>Journal of the American Heart Association</i> , 2013, 2, e000399.	3.7	66
125	NT-proBNP Goal Achievement Is Associated With Significant Reverse Remodeling and Improved Clinical Outcomes in HFrEF. <i>JACC: Heart Failure</i> , 2019, 7, 158-168.	4.1	65
126	The impact of arrhythmias in acute heart failure. <i>Journal of Cardiac Failure</i> , 2004, 10, 279-284.	1.7	64

#	ARTICLE	IF	CITATIONS
127	Soluble ST2 in Heart Failure With Preserved Ejection Fraction. <i>Journal of the American Heart Association</i> , 2017, 6, .	3.7	64
128	A secondary analysis of the CHOIR trial shows that comorbid conditions differentially affect outcomes during anemia treatment. <i>Kidney International</i> , 2010, 77, 239-246.	5.2	62
129	Treatment of subcutaneous and intracranial brain tumor xenografts with O 6-benzylguanine and 1,3-bis(2-chloroethyl)-1-nitrosourea. <i>Cancer Chemotherapy and Pharmacology</i> , 1993, 32, 471-476.	2.3	61
130	Acute heart failure: Multiple clinical profiles and mechanisms require tailored therapy. <i>International Journal of Cardiology</i> , 2010, 144, 175-179.	1.7	61
131	Clinical Impact of Concomitant Tricuspid Valve Procedures During Left Ventricular Assist Device Implantation. <i>Annals of Thoracic Surgery</i> , 2011, 92, 1414-1419.	1.3	60
132	Design of the RELAXin in Acute Heart Failure Study. <i>American Heart Journal</i> , 2012, 163, 149-155.e1.	2.7	60
133	Valvular Heart Disease in Patients Supported With Left Ventricular Assist Devices. <i>Circulation: Heart Failure</i> , 2014, 7, 215-222.	3.9	60
134	In-hospital worsening heart failure. <i>European Journal of Heart Failure</i> , 2015, 17, 1104-1113.	7.1	60
135	Assessment of Omecamtiv Mecarbil for the Treatment of Patients With Severe Heart Failure. <i>JAMA Cardiology</i> , 2022, 7, 26.	6.1	59
136	Hyponatremia and Long-Term Outcomes in Chronic Heart Failure—An Observational Study From the Duke Databank for Cardiovascular Diseases. <i>Journal of Cardiac Failure</i> , 2012, 18, 74-81.	1.7	58
137	High-Sensitivity C-Reactive Protein in Acute Heart Failure: Insights From the ASCEND-HF Trial. <i>Journal of Cardiac Failure</i> , 2014, 20, 319-326.	1.7	57
138	Effects of serelaxin in subgroups of patients with acute heart failure: results from RELAX-AHF. <i>European Heart Journal</i> , 2013, 34, 3128-3136.	2.2	56
139	Effect of Serelaxin on Mode of Death in Acute Heart Failure. <i>Journal of the American College of Cardiology</i> , 2014, 64, 1591-1598.	2.8	56
140	A Test in Context. <i>Journal of the American College of Cardiology</i> , 2016, 67, 330-337.	2.8	56
141	Thrombolytic Therapy for Thrombosis of Continuous Flow Ventricular Assist Devices. <i>Journal of Cardiac Failure</i> , 2014, 20, 91-97.	1.7	55
142	Splanchnic nerve block for decompensated chronic heart failure: splanchnic-HF. <i>European Heart Journal</i> , 2018, 39, 4255-4256.	2.2	54
143	Natriuretic Peptide Response and Outcomes in Chronic Heart Failure With Reduced Ejection Fraction. <i>Journal of the American College of Cardiology</i> , 2019, 74, 1205-1217.	2.8	54
144	Defining Heart Failure End Points in ST-Segment Elevation Myocardial Infarction Trials. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2012, 5, 594-600.	2.2	53

#	ARTICLE	IF	CITATIONS
145	Natriuretic Peptides as Inclusion Criteria in Clinical Trials. <i>JACC: Heart Failure</i> , 2020, 8, 347-358.	4.1	53
146	Vasodilators in the treatment of acute heart failure: what we know, what we don't. <i>Heart Failure Reviews</i> , 2009, 14, 299-307.	3.9	52
147	Noncardiac Comorbidities and Acute Heart Failure Patients. <i>Heart Failure Clinics</i> , 2013, 9, 359-367.	2.1	52
148	Obese-Inflammatory Phenotypes in Heart Failure With Preserved Ejection Fraction. <i>Circulation: Heart Failure</i> , 2020, 13, e006414.	3.9	52
149	The effects of exercise on cardiovascular biomarkers in patients with chronic heart failure. <i>American Heart Journal</i> , 2014, 167, 193-202.e1.	2.7	50
150	Effect of angiotensin-converting enzyme inhibitors, beta blockers, statins, and aspirin on C-reactive protein levels in outpatients with heart failure. <i>American Journal of Cardiology</i> , 2004, 93, 783-785.	1.6	49
151	Galectin-3 in Heart Failure With Preserved Ejection Fraction. <i>JACC: Heart Failure</i> , 2015, 3, 245-252.	4.1	49
152	Use of High-Sensitivity Troponin T to Identify Patients With Acute Heart Failure at Lower Risk for Adverse Outcomes. <i>JACC: Heart Failure</i> , 2016, 4, 591-599.	4.1	49
153	Same Bridge, New Destinations. <i>Journal of the American College of Cardiology</i> , 2006, 47, 930-932.	2.8	48
154	Phase III clinical trial end points in acute heart failure syndromes: A virtual roundtable with the acute heart failure syndromes international working group. <i>American Heart Journal</i> , 2009, 157, 957-970.	2.7	48
155	Intensification of Medication Therapy for Cardiorenal Syndrome in Acute Decompensated Heart Failure. <i>Journal of Cardiac Failure</i> , 2016, 22, 26-32.	1.7	48
156	Treatment with 24-hour isartoxime infusion in patients hospitalised for acute heart failure: a randomised, placebo-controlled trial. <i>European Journal of Heart Failure</i> , 2020, 22, 1684-1693.	7.1	48
157	Increased mortality with elevated plasma endothelin-1 in acute heart failure: an ASCEND-HF biomarker substudy. <i>European Journal of Heart Failure</i> , 2016, 18, 290-297.	7.1	47
158	Omecamtiv mecarbil in chronic heart failure with reduced ejection fraction: GALACTIC-HF baseline characteristics and comparison with contemporary clinical trials. <i>European Journal of Heart Failure</i> , 2020, 22, 2160-2171.	7.1	47
159	Atrial Natriuretic Peptide and Treatment With Sacubitril/Valsartan in Heart Failure With Reduced Ejection Fraction. <i>JACC: Heart Failure</i> , 2021, 9, 127-136.	4.1	47
160	Prospective evaluation of the association between hemoglobin concentration and quality of life in patients with heart failure. <i>American Heart Journal</i> , 2009, 158, 965-971.	2.7	46
161	Significance of hyponatremia in heart failure. <i>Heart Failure Reviews</i> , 2012, 17, 17-26.	3.9	46
162	Differential Response to Low-Dose Dopamine or Low-Dose Nesiritide in Acute Heart Failure With Reduced or Preserved Ejection Fraction. <i>Circulation: Heart Failure</i> , 2016, 9, .	3.9	46

#	ARTICLE	IF	CITATIONS
163	Prospective assessment of the occurrence of anemia in patients with heart failure: Results from the Study of Anemia in a Heart Failure Population (STAMINA-HFP) Registry. <i>American Heart Journal</i> , 2009, 157, 926-932.	2.7	45
164	Prognostic Value of Baseline and Changes in Circulating Soluble ST2 Levels and the Effects of Nesiritide in Acute Decompensated Heart Failure. <i>JACC: Heart Failure</i> , 2016, 4, 68-77.	4.1	45
165	Accelerometer-Measured Daily Activity in Heart Failure With Preserved Ejection Fraction. <i>Circulation: Heart Failure</i> , 2017, 10, e003878.	3.9	45
166	Splanchnic Nerve Block for Chronic Heart Failure. <i>JACC: Heart Failure</i> , 2020, 8, 742-752.	4.1	44
167	Improvements in Signs and Symptoms During Hospitalization for Acute Heart Failure Follow Different Patterns and Depend on the Measurement Scales Used: An International, Prospective Registry to Evaluate the Evolution of Measures of Disease Severity in Acute Heart Failure (MEASURE-AHF). <i>Journal of Cardiac Failure</i> , 2008, 14, 777-784.	1.7	43
168	Renal Effects of Intensive Volume Removal in Heart Failure Patients With Preexisting Worsening Renal Function. <i>Circulation: Heart Failure</i> , 2019, 12, e005552.	3.9	43
169	Acute heart failure associated with high admission blood pressure - A distinct vascular disorder?. <i>European Journal of Heart Failure</i> , 2007, 9, 178-183.	7.1	42
170	Aetiology, timing and clinical predictors of early vs. late readmission following index hospitalization for acute heart failure: insights from ASCEND-HF. <i>European Journal of Heart Failure</i> , 2018, 20, 304-314.	7.1	42
171	Early Management of Patients With Acute Heart Failure: State of the Art and Future Directions A Consensus Document from the SAEM/HFSA Acute Heart Failure Working Group. <i>Academic Emergency Medicine</i> , 2015, 22, 94-112.	1.8	41
172	Racial Differences in the Characteristics of Patients Admitted for Acute Decompensated Heart Failure and Their Relation to Outcomes: Results From the OPTIME-CHF Trial. <i>Journal of Cardiac Failure</i> , 2006, 12, 684-688.	1.7	40
173	Diuretic Management in Heart Failure. <i>Congestive Heart Failure</i> , 2010, 16, S68-72.	2.0	40
174	Troponin T levels in patients with acute heart failure: clinical and prognostic significance of their detection and release during hospitalisation. <i>Clinical Research in Cardiology</i> , 2012, 101, 663-672.	3.3	40
175	Association between adrenergic receptor genotypes and beta-blocker dose in heart failure patients: analysis from the HF ACTION DNA substudy. <i>European Journal of Heart Failure</i> , 2013, 15, 258-266.	7.1	40
176	Predictors of early dyspnoea relief in acute heart failure and the association with 30-day outcomes: findings from ASCEND-HF. <i>European Journal of Heart Failure</i> , 2013, 15, 456-464.	7.1	39
177	Ten-Year Experience With Extended Criteria Cardiac Transplantation. <i>Circulation: Heart Failure</i> , 2013, 6, 1230-1238.	3.9	39
178	Liver Function, In-Hospital, and Post-Discharge Clinical Outcome in Patients With Acute Heart Failure Results From the Relaxin for the Treatment of Patients With Acute Heart Failure Study. <i>Journal of Cardiac Failure</i> , 2014, 20, 407-413.	1.7	38
179	Worsening heart failure during hospitalization for acute heart failure: Insights from the Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure (ASCEND-HF). <i>American Heart Journal</i> , 2015, 170, 298-305.	2.7	38
180	Myocardial Damage Detected by Late Gadolinium Enhancement Cardiac Magnetic Resonance Is Uncommon in Peripartum Cardiomyopathy. <i>Journal of the American Heart Association</i> , 2017, 6, .	3.7	38

#	ARTICLE	IF	CITATIONS
181	Impact of Left Ventricular Assist Device Bridging on Posttransplant Outcomes. <i>Annals of Thoracic Surgery</i> , 2009, 88, 1457-1461.	1.3	37
182	Effect of admission oral diuretic dose on response to continuous versus bolus intravenous diuretics in acute heart failure: An analysis from Diuretic Optimization Strategies in Acute Heart Failure. <i>American Heart Journal</i> , 2012, 164, 862-868.	2.7	37
183	High-Density Lipoprotein Particle Subfractions in Heart Failure With Preserved or Reduced Ejection Fraction. <i>Journal of the American College of Cardiology</i> , 2019, 73, 177-186.	2.8	37
184	Splanchnic nerve modulation in heart failure: mechanistic overview, initial clinical experience, and safety considerations. <i>European Journal of Heart Failure</i> , 2021, 23, 1076-1084.	7.1	37
185	A Global Ranking Approach to End Points in Trials of Mechanical Circulatory Support Devices. <i>Journal of Cardiac Failure</i> , 2008, 14, 368-372.	1.7	36
186	The clinical course of health status and association with outcomes in patients hospitalized for heart failure: insights from ASCEND-HF. <i>European Journal of Heart Failure</i> , 2016, 18, 306-313.	7.1	36
187	Cardiac transplantation for older patients: Characteristics and outcomes in the septuagenarian population. <i>Journal of Heart and Lung Transplantation</i> , 2016, 35, 362-369.	0.6	36
188	Clinical factors related to morbidity and mortality in high-risk heart failure patients: the GUIDE-HF predictive model and risk score. <i>European Journal of Heart Failure</i> , 2019, 21, 770-778.	7.1	36
189	Early worsening heart failure in patients admitted with acute heart failure – a new outcome measure associated with long-term prognosis?. <i>Fundamental and Clinical Pharmacology</i> , 2009, 23, 633-639.	1.9	35
190	Comparative Assessment of Short-Term Adverse Events in Acute Heart Failure With Cystatin C and Other Estimates of Renal Function. <i>JACC: Heart Failure</i> , 2015, 3, 40-49.	4.1	35
191	Conduct of Clinical Trials in the Era of COVID-19. <i>Journal of the American College of Cardiology</i> , 2020, 76, 2368-2378.	2.8	35
192	Utilizing mobile technologies to improve physical activity and medication adherence in patients with heart failure and diabetes mellitus: Rationale and design of the TARGET-HF-DM Trial. <i>American Heart Journal</i> , 2019, 211, 22-33.	2.7	34
193	Worsening renal function in acute heart failure in the context of diuretic response. <i>European Journal of Heart Failure</i> , 2022, 24, 365-374.	7.1	34
194	Comparison of Clinical Characteristics and Long-Term Outcomes of Patients With Ischemic Cardiomyopathy With Versus Without Angina Pectoris (from the Duke Databank for Cardiovascular) <i>Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5</i>	1.8	32
195	N-terminal pro-brain natriuretic peptide and exercise capacity in chronic heart failure: Data from the Heart Failure and a Controlled Trial Investigating Outcomes of Exercise Training (HF-ACTION) study. <i>American Heart Journal</i> , 2009, 158, S37-S44.	2.7	31
196	United States Stock Market Performance and Acute Myocardial Infarction Rates in 2008–2009 (from) <i>Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5</i>	1.6	31
197	Thromboembolism and Antithrombotic Therapy in Patients With Heart Failure in Sinus Rhythm. <i>Circulation: Heart Failure</i> , 2011, 4, 361-368.	3.9	31
198	Surfing the Biomarker Tsunami at JACC: Heart Failure. <i>JACC: Heart Failure</i> , 2013, 1, 213-215.	4.1	31

#	ARTICLE	IF	CITATIONS
199	Sildenafil Treatment in Heart Failure With Preserved Ejection Fraction. <i>JAMA Cardiology</i> , 2017, 2, 896.	6.1	31
200	Mortality in primary and secondary myocarditis. <i>American Heart Journal</i> , 2004, 147, 746-750.	2.7	30
201	Loop diuretics in heart failure. <i>Heart Failure Reviews</i> , 2012, 17, 305-311.	3.9	30
202	Learning from recent trials and shaping the future of acute heart failure trials. <i>American Heart Journal</i> , 2013, 166, 629-635.	2.7	30
203	The Impact of Worsening Heart Failure in the United States. <i>Heart Failure Clinics</i> , 2015, 11, 603-614.	2.1	30
204	Rationale and Design of the ATHENA-HF Trial. <i>JACC: Heart Failure</i> , 2016, 4, 726-735.	4.1	30
205	Clinical Implications of Cluster Analysis-Based Classification of Acute Decompensated Heart Failure and Correlation with Bedside Hemodynamic Profiles. <i>PLoS ONE</i> , 2016, 11, e0145881.	2.5	30
206	Multi-marker strategies in heart failure: clinical and statistical approaches. <i>Heart Failure Reviews</i> , 2010, 15, 343-349.	3.9	28
207	Reverse Cardiac Remodeling and Outcome After Initiation of Sacubitril/Valsartan. <i>Circulation: Heart Failure</i> , 2020, 13, e006946.	3.9	28
208	Endpoints in Heart Failure Drug Development. <i>JACC: Heart Failure</i> , 2020, 8, 429-440.	4.1	28
209	Splanchnic Nerve Block Mediated Changes in Stressed Blood Volume in Heart Failure. <i>JACC: Heart Failure</i> , 2021, 9, 293-300.	4.1	28
210	Implantable Cardioverter-Defibrillator Eligibility After Initiation of Sacubitril/Valsartan in Chronic Heart Failure: Insights From PROVE-HF. <i>Circulation</i> , 2021, 144, 180-182.	1.6	28
211	Link between decisions regarding resuscitation and preferences for quality over length of life with heart failure. <i>European Journal of Heart Failure</i> , 2012, 14, 45-53.	7.1	27
212	Targeting the Kidney in Acute Heart Failure: Can Old Drugs Provide New Benefit?. <i>Circulation: Heart Failure</i> , 2013, 6, 1087-1094.	3.9	27
213	Biomarker-based risk prediction in the community. <i>European Journal of Heart Failure</i> , 2016, 18, 1342-1350.	7.1	27
214	Relationship between baseline systolic blood pressure and long-term outcomes in acute heart failure patients treated with TRV027: an exploratory subgroup analysis of BLAST-AHF. <i>Clinical Research in Cardiology</i> , 2018, 107, 170-181.	3.3	27
215	Association Between Angiotensin Receptor-Nepriylsin Inhibition, Cardiovascular Biomarkers, and Cardiac Remodeling in Heart Failure With Reduced Ejection Fraction. <i>Circulation: Heart Failure</i> , 2021, 14, e008410.	3.9	27
216	Tolvaptan in Patients Hospitalized With Acute Heart Failure. <i>Circulation: Heart Failure</i> , 2015, 8, 997-1005.	3.9	26

#	ARTICLE	IF	CITATIONS
217	Adverse Renal Response to Decongestion in the Obese Phenotype of Heart Failure With Preserved Ejection Fraction. <i>Journal of Cardiac Failure</i> , 2020, 26, 101-107.	1.7	26
218	In-Hospital Therapy for Heart Failure With Reduced Ejection Fraction in the United States. <i>JACC: Heart Failure</i> , 2020, 8, 943-953.	4.1	26
219	Provider Perspectives on the Feasibility and Utility of Routine Patient-Reported Outcomes Assessment in Heart Failure: A Qualitative Analysis. <i>Journal of the American Heart Association</i> , 2020, 9, e013047.	3.7	26
220	Treatment of HF in an Era of Multiple Therapies. <i>JACC: Heart Failure</i> , 2021, 9, 1-12.	4.1	26
221	Implantable cardioverter-defibrillators in heart failure patients with reduced ejection fraction and diabetes. <i>European Journal of Heart Failure</i> , 2018, 20, 1031-1038.	7.1	24
222	Breastfeeding, Cellular Immune Activation, and Myocardial Recovery in Peripartum Cardiomyopathy. <i>JACC Basic To Translational Science</i> , 2019, 4, 291-300.	4.1	24
223	Effects of serelaxin in patients admitted for acute heart failure: a meta-analysis. <i>European Journal of Heart Failure</i> , 2020, 22, 315-329.	7.1	24
224	Mechanisms and Models in Heart Failure. <i>Circulation Research</i> , 2021, 128, 1435-1450.	4.5	24
225	Hyponatraemia in acute heart failure is a marker of increased mortality but not when associated with hyperglycaemia. <i>European Journal of Heart Failure</i> , 2008, 10, 196-200.	7.1	23
226	Serum Bicarbonate in Acute Heart Failure: Relationship to Treatment Strategies and Clinical Outcomes. <i>Journal of Cardiac Failure</i> , 2016, 22, 738-742.	1.7	23
227	High-Sensitivity Troponin I in Hospitalized and Ambulatory Patients With Heart Failure With Preserved Ejection Fraction: Insights From the Heart Failure Clinical Research Network. <i>Journal of the American Heart Association</i> , 2018, 7, e010364.	3.7	22
228	Hepatorenal dysfunction identifies high-risk patients with acute heart failure: insights from the RELAX-AHF trial. <i>ESC Heart Failure</i> , 2019, 6, 1188-1198.	3.1	22
229	Care Optimization Through Patient and Hospital Engagement Clinical Trial for Heart Failure: Rationale and design of CONNECT-HF. <i>American Heart Journal</i> , 2020, 220, 41-50.	2.7	22
230	Circulating Nprilysin in Patients With Heart Failure and Preserved Ejection Fraction. <i>JACC: Heart Failure</i> , 2020, 8, 70-80.	4.1	21
231	Sex-based differences in biomarkers, health status, and reverse cardiac remodelling in patients with heart failure with reduced ejection fraction treated with sacubitril/valsartan. <i>European Journal of Heart Failure</i> , 2020, 22, 2018-2025.	7.1	21
232	Relationship between left ventricular ejection fraction and cardiovascular outcomes following hospitalization for heart failure: insights from the RELAX-AHF2 trial. <i>European Journal of Heart Failure</i> , 2020, 22, 726-738.	7.1	21
233	Infectious Complications in Extended Criteria Heart Transplantation. <i>Journal of Heart and Lung Transplantation</i> , 2008, 27, 1217-1221.	0.6	20
234	Advances in the surgical treatment of heart failure. <i>Current Opinion in Cardiology</i> , 2008, 23, 249-253.	1.8	20

#	ARTICLE	IF	CITATIONS
235	Patterns of leukocyte counts on admissions for acute heart failure “presentation and outcome” results from a community based registry. <i>International Journal of Cardiology</i> , 2011, 148, 17-22.	1.7	20
236	Economic and Quality-of-Life Outcomes of Natriuretic Peptide “Guided Therapy for Heart Failure. <i>Journal of the American College of Cardiology</i> , 2018, 72, 2551-2562.	2.8	20
237	Rationale and design for the development of a novel nitroxyl donor in patients with acute heart failure. <i>European Journal of Heart Failure</i> , 2019, 21, 1022-1031.	7.1	20
238	Improvement of Health Status Following Initiation of Sacubitril/Valsartan in Heart Failure and Reduced Ejection Fraction. <i>JACC: Heart Failure</i> , 2021, 9, 42-51.	4.1	20
239	Frailty, Guideline-Directed Medical Therapy, and Outcomes in HFrEF. <i>JACC: Heart Failure</i> , 2022, 10, 266-275.	4.1	20
240	Rational use of inotropic therapy in heart failure. <i>Current Cardiology Reports</i> , 2001, 3, 108-113.	2.9	19
241	Circulating Kidney Injury Molecule-1 Levels in Acute Heart Failure. <i>JACC: Heart Failure</i> , 2015, 3, 777-785.	4.1	19
242	Diuretic Treatment in Heart Failure. <i>New England Journal of Medicine</i> , 2018, 378, 683-685.	27.0	19
243	Spironolactone in Acute Heart Failure Patients With Renal Dysfunction and Risk Factors for Diuretic Resistance: From the ATHENA-HF Trial. <i>Canadian Journal of Cardiology</i> , 2019, 35, 1097-1105.	1.7	19
244	Galectin-3 in Heart Failure: More Answers or More Questions?. <i>Journal of the American Heart Association</i> , 2012, 1, e004374.	3.7	18
245	Racial and Ethnic Differences in Biomarkers, Health Status, and Cardiac Remodeling in Patients With Heart Failure With Reduced Ejection Fraction Treated With Sacubitril/Valsartan. <i>Circulation: Heart Failure</i> , 2020, 13, e007829.	3.9	18
246	Low Lymphocyte Ratio as a Novel Prognostic Factor in Acute Heart Failure: Results from the Pre-RELAX-AHF Study. <i>Cardiology</i> , 2010, 117, 190-196.	1.4	17
247	Characteristics and Outcomes of Patients With Heart Failure and Discordant Findings by Right-Sided Heart Catheterization and Cardiopulmonary Exercise Testing. <i>American Journal of Cardiology</i> , 2014, 114, 1059-1064.	1.6	17
248	Comparison of 2-Year Outcomes of Extended Criteria Cardiac Transplantation Versus Destination Left Ventricular Assist Device Therapy Using Continuous Flow. <i>American Journal of Cardiology</i> , 2015, 116, 573-579.	1.6	17
249	Pulmonary Hypertension in the Era of Mechanical Circulatory Support. <i>ASAIO Journal</i> , 2016, 62, 505-512.	1.6	17
250	Sex differences in early dyspnea relief between men and women hospitalized for acute heart failure: insights from the RELAX-AHF study. <i>Clinical Research in Cardiology</i> , 2017, 106, 280-292.	3.3	17
251	Effects of a Novel Nitroxyl Donor in Acute Heart Failure. <i>JACC: Heart Failure</i> , 2021, 9, 146-157.	4.1	17
252	Relationship Between Anemia and Health Care Costs in Heart Failure. <i>Journal of Cardiac Failure</i> , 2009, 15, 843-849.	1.7	16

#	ARTICLE	IF	CITATIONS
253	Prospective evaluation of the association between cardiac troponin T and markers of disturbed erythropoiesis in patients with heart failure. <i>American Heart Journal</i> , 2010, 160, 1142-1148.	2.7	16
254	Effects of serelaxin in acute heart failure patients with renal impairment: results from RELAX-AHF. <i>Clinical Research in Cardiology</i> , 2016, 105, 727-737.	3.3	16
255	Interleukin-6 and Outcomes in Acute Heart Failure: An ASCEND-HF Substudy. <i>Journal of Cardiac Failure</i> , 2021, 27, 670-676.	1.7	16
256	Clinical Outcomes With Metformin and Sulfonylurea Therapies Among Patients With Heart Failure and Diabetes. <i>JACC: Heart Failure</i> , 2022, 10, 198-210.	4.1	16
257	Biomarker guided therapy for heart failure: focus on natriuretic peptides. <i>Heart Failure Reviews</i> , 2010, 15, 351-370.	3.9	15
258	Subcutaneous B-Type Natriuretic Peptide for Treatment of Heart Failure. <i>Journal of the American College of Cardiology</i> , 2012, 60, 2313-2315.	2.8	15
259	Trajectory of Congestion Metrics by Ejection Fraction in Patients With Acute Heart Failure (from the Tj ETQq1 1 0.784314 rgBT /Overlock	1.6	15
260	Circulating T-Cell Subsets, Monocytes, and Natural Killer Cells in Peripartum Cardiomyopathy: Results From the Multicenter IPAC Study. <i>Journal of Cardiac Failure</i> , 2018, 24, 33-42.	1.7	15
261	Racial Differences in Diuretic Efficiency, Plasma Renin, and Rehospitalization in Subjects With Acute Heart Failure. <i>Circulation: Heart Failure</i> , 2020, 13, e006827.	3.9	15
262	Effects of omecamtiv mecarbil in heart failure with reduced ejection fraction according to blood pressure: the GALACTIC-HF trial. <i>European Heart Journal</i> , 2022, 43, 5006-5016.	2.2	15
263	Nesiritide in patients hospitalized for acute heart failure: does timing matter? Implication for future acute heart failure trials. <i>European Journal of Heart Failure</i> , 2016, 18, 684-692.	7.1	14
264	Outpatient versus inpatient worsening heart failure: distinguishing biology and risk from location of care. <i>European Journal of Heart Failure</i> , 2019, 21, 121-124.	7.1	14
265	Racial Differences in Serial NT-proBNP Levels in Heart Failure Management. <i>Circulation</i> , 2020, 142, 1018-1020.	1.6	14
266	Probabilistic Readjudication of Heart Failure Hospitalization Events in the PARAGON-HF Study. <i>Circulation</i> , 2021, 143, 2316-2318.	1.6	14
267	Natriuretic Peptide-Guided Therapy for Heart Failure. <i>Circulation Journal</i> , 2011, 75, 2031-2037.	1.6	13
268	Mode of Death After Acute Heart Failure Hospitalization—A Clue to Possible Mechanisms. <i>Circulation Journal</i> , 2016, 80, 17-23.	1.6	13
269	Implications of Alternative Hepatorenal Prognostic Scoring Systems in Acute Heart Failure (from the Tj ETQq1 1 0.784314 rgBT /Overlock	1.6	13
270	Cardiovascular Disease: Impact of Biomarkers, Proteomics, and Genomics. <i>Clinical Chemistry</i> , 2017, 63, 1-4.	3.2	13

#	ARTICLE	IF	CITATIONS
271	Clinical Significance of Early Fluid and Weight Change During Acute Heart Failure Hospitalization. <i>Journal of Cardiac Failure</i> , 2018, 24, 542-549.	1.7	13
272	Haemodynamic effects of the nitroxyl donor cimlanod (<sc>BMS</sc>â€œ986231) in chronic heart failure: a randomized trial. <i>European Journal of Heart Failure</i> , 2021, 23, 1147-1155.	7.1	13
273	Permutation criteria to evaluate multiple clinical endpoints in a proof-of-concept study: lessons from Pre-RELAX-AHF. <i>Clinical Research in Cardiology</i> , 2011, 100, 745-753.	3.3	12
274	Obesity and the Response to Intensified Diuretic Treatment in Decompensated Heart Failure: A DOSE Trial Substudy. <i>Journal of Cardiac Failure</i> , 2012, 18, 837-844.	1.7	12
275	Novel approach to classifying patients with pulmonary arterial hypertension using cluster analysis. <i>Pulmonary Circulation</i> , 2017, 7, 486-493.	1.7	12
276	Interaction of Body Mass Index on the Association Between Nâ€œTerminalâ€œProâ€œBâ€œType Natriuretic Peptide and Morbidity and Mortality in Patients With Acute Heart Failure: Findings From ASCENDâ€œHF (Acute Study) Tj ETQq0 0.0 rgBT /Qyerlock 10 Association, 2018, 7, .	3.7	12
277	Maternal Obesity Affects Cardiac Remodeling and Recovery in Women with Peripartum Cardiomyopathy. <i>American Journal of Perinatology</i> , 2019, 36, 476-483.	1.4	12
278	Cause of Death in Patients With Acuteâ€œHeartâ€œFailure. <i>JACC: Heart Failure</i> , 2020, 8, 999-1008.	4.1	12
279	What's Next for Acute Heart Failure Research?. <i>Academic Emergency Medicine</i> , 2018, 25, 85-93.	1.8	11
280	Prognostic Implications of Changes in Amino-Terminal Proâ€œB-Type Natriuretic Peptide in Acute Decompensated Heart Failure: Insights From ASCEND-HF. <i>Journal of Cardiac Failure</i> , 2019, 25, 703-711.	1.7	11
281	Building the Foundation for a New Era of Quadruple Therapy in Heart Failure. <i>Circulation</i> , 2020, 141, 112-114.	1.6	11
282	Ultrafiltration in Acute Heart Failure: Implications of Ejection Fraction and Early Response to Treatment From CARRESSâ€œHF. <i>Journal of the American Heart Association</i> , 2020, 9, e015752.	3.7	11
283	Clinical and Research Considerations for Patients With Hypertensive Acute Heart Failure: A Consensus Statement from the Society for Academic Emergency Medicine and the Heart Failure Society of America Acute Heart Failure Working Group. <i>Academic Emergency Medicine</i> , 2016, 23, 922-931.	1.8	10
284	History of Atrial Fibrillation and Trajectory of Decongestion in Acuteâ€œHeart Failure. <i>JACC: Heart Failure</i> , 2019, 7, 47-55.	4.1	10
285	Cardiac Myosin Activator Omecamtiv Mecarbil Improves Left Ventricular Myocardial Deformation in Chronic Heart Failure. <i>Circulation: Heart Failure</i> , 2020, 13, e008007.	3.9	10
286	Association of left ventricular ejection fraction with worsening renal function in patients with acute heart failure: insights from the <sc>RELAXâ€œAHF</sc>â€œ2 study. <i>European Journal of Heart Failure</i> , 2021, 23, 58-67.	7.1	10
287	The effect of the cardiac myosin activator, omecamtiv mecarbil, on right ventricular structure and function in chronic systolic heart failure (<sc>COSMIC</sc>â€œ<sc>HF</sc>). <i>European Journal of Heart Failure</i> , 2021, 23, 1052-1056.	7.1	10
288	Reduction in Body Weight but Worsening Renal Function with Late Ultrafiltration for Treatment of Acute Decompensated Heart Failure. <i>Cardiology</i> , 2012, 123, 145-153.	1.4	9

#	ARTICLE	IF	CITATIONS
289	Fluid removal in acute heart failure. <i>Current Opinion in Critical Care</i> , 2014, 20, 478-483.	3.2	9
290	Evaluation of the Incremental Prognostic Utility of Increasingly Complex Testing in Chronic Heart Failure. <i>Circulation: Heart Failure</i> , 2015, 8, 709-716.	3.9	9
291	Composite End Points in Acute Heart Failure Research: Data Simulations Illustrate the Limitations. <i>Canadian Journal of Cardiology</i> , 2016, 32, 1356.e21-1356.e28.	1.7	9
292	Day vs night: Does time of presentation matter in acute heart failure? A secondary analysis from the RELAX-AHF trial. <i>American Heart Journal</i> , 2017, 187, 62-69.	2.7	9
293	Circulating Cardiac Troponin I Levels Measured by a Novel Highly Sensitive Assay in Acute Decompensated Heart Failure: Insights From the ASCEND-HF Trial. <i>Journal of Cardiac Failure</i> , 2018, 24, 512-519.	1.7	9
294	Is plasma renin activity associated with worse outcomes in acute heart failure? A secondary analysis from the BLAST-AHF trial. <i>European Journal of Heart Failure</i> , 2019, 21, 1561-1570.	7.1	9
295	Best Practices for Prognostic Evaluation of a Patient With Transthyretin Amyloid Cardiomyopathy. <i>JACC: CardioOncology</i> , 2019, 1, 273-279.	4.0	9
296	The Urgency of Doing. <i>JACC: Heart Failure</i> , 2019, 7, 22-24.	4.1	9
297	Effects of Omecamtiv Mecarbil on Symptoms and Health-Related Quality of Life in Patients With Chronic Heart Failure. <i>Circulation: Heart Failure</i> , 2020, 13, e007814.	3.9	9
298	Diagnosis and Management of Acute Heart Failure Syndromes. , 2012, , 517-542.		9
299	Unraveling the Mystery of Troponin Elevation in Heart Failure. <i>Journal of the American College of Cardiology</i> , 2018, 71, 2917-2918.	2.8	9
300	Anaemia and coronary artery disease severity in patients with heart failure. <i>European Journal of Heart Failure</i> , 2006, 8, 54-57.	7.1	8
301	Rapid Clinical Assessment of Patients with Acute Heart Failure: First Blood Pressure and Oxygen Saturation "Is That All We Need?". <i>Cardiology</i> , 2009, 114, 75-82.	1.4	8
302	How to use diuretics in heart failure. <i>Current Treatment Options in Cardiovascular Medicine</i> , 2009, 11, 426-432.	0.9	8
303	Serelaxin in acute heart failure patients with and without atrial fibrillation: a secondary analysis of the RELAX-AHF trial. <i>Clinical Research in Cardiology</i> , 2017, 106, 444-456.	3.3	8
304	Dose Response of β -Blockers in Adrenergic Receptor Polymorphism Genotypes. <i>Circulation Genomic and Precision Medicine</i> , 2018, 11, e002210.	3.6	8
305	Effects of Liraglutide on Worsening Renal Function Among Patients With Heart Failure With Reduced Ejection Fraction. <i>Circulation: Heart Failure</i> , 2020, 13, e006758.	3.9	8
306	Growth differentiation factor-15, treatment with liraglutide, and clinical outcomes among patients with heart failure. <i>ESC Heart Failure</i> , 2021, 8, 2608-2616.	3.1	8

#	ARTICLE	IF	CITATIONS
307	Circulating long chain acylcarnitines and outcomes in diabetic heart failure: an HF-ACTION clinical trial substudy. <i>Cardiovascular Diabetology</i> , 2021, 20, 161.	6.8	8
308	Implantable left ventricular assist devices: new hope for patients with end-stage heart failure. <i>North Carolina Medical Journal</i> , 2006, 67, 110-5.	0.2	8
309	Developments in Exercise Capacity Assessment in Heart Failure Clinical Trials and the Rationale for the Design of METEORIC-HF. <i>Circulation: Heart Failure</i> , 2022, 15, CIRCHEARTFAILURE121008970.	3.9	8
310	Between Scylla and Charybdis: The choice of inotropic agent for decompensated heart failure. <i>American Heart Journal</i> , 2001, 142, 932-933.	2.7	7
311	Biomarkers as Surrogate End Points in Heart Failure Trials. <i>Heart Failure Clinics</i> , 2011, 7, 501-507.	2.1	7
312	Approaches to Decongestion in Patients with Acute Decompensated Heart Failure. <i>Current Cardiology Reports</i> , 2013, 15, 335.	2.9	7
313	Natriuretic Peptides and Primary Prevention. <i>Journal of the American College of Cardiology</i> , 2013, 62, 1373-1375.	2.8	7
314	Implications of Using Different Definitions on Outcomes in Worsening Heart Failure. <i>Circulation: Heart Failure</i> , 2016, 9, .	3.9	7
315	Challenges and Potential Improvements to Patient Access to Pharmaceuticals. <i>Circulation</i> , 2020, 142, 790-798.	1.6	7
316	Annexin A1 is a Potential Novel Biomarker of Congestion in Acute Heart Failure. <i>Journal of Cardiac Failure</i> , 2020, 26, 727-732.	1.7	7
317	Effects of Atrial Fibrillation on Heart Failure Outcomes and NT-proBNP Levels in the GUIDE-IT Trial. <i>Mayo Clinic Proceedings Innovations, Quality & Outcomes</i> , 2021, 5, 447-455.	2.4	7
318	Association of Early Blood Pressure Decrease and Renal Function With Prognosis in Acute Heart Failure. <i>JACC: Heart Failure</i> , 2021, 9, 890-903.	4.1	7
319	Health System Level Performance in Prescribing Guideline-Directed Medical Therapy for Patients with HF with Reduced Ejection Fraction: Results from the CONNECT-HF Trial. <i>Journal of Cardiac Failure</i> , 2022, , .	1.7	7
320	Clinical Prediction Models for Heart Failure Hospitalization in Type 2 Diabetes: A Systematic Review and Meta-Analysis. <i>Journal of the American Heart Association</i> , 2022, 11, e024833.	3.7	7
321	The Potential Impact of Expanding Cardiac Rehabilitation in Heart Failure. <i>Journal of the American College of Cardiology</i> , 2016, 68, 977-978.	2.8	6
322	Plasma Levels of MicroRNA-155 Are Upregulated with Long-Term Left Ventricular Assist Device Support. <i>ASAIO Journal</i> , 2017, 63, 536-541.	1.6	6
323	Design of a Lean Case Report Form for Heart Failure Therapeutic Development. <i>JACC: Heart Failure</i> , 2019, 7, 913-921.	4.1	6
324	Are existing and emerging biomarkers associated with cardiorespiratory fitness in patients with chronic heart failure?. <i>American Heart Journal</i> , 2020, 220, 97-107.	2.7	6

#	ARTICLE	IF	CITATIONS
325	Heart Failure Clinical Trial Operations During the COVID-19 Pandemic. <i>Circulation: Heart Failure</i> , 2020, 13, e007456.	3.9	6
326	Differences in NT-proBNP Response and Prognosis in Men and Women With Heart Failure With Reduced Ejection Fraction. <i>Journal of the American Heart Association</i> , 2021, 10, e019712.	3.7	6
327	Characteristics and Outcomes of Patients With Heart Failure With Reduced Ejection Fraction After a Recent Worsening Heart Failure Event. <i>Journal of the American Heart Association</i> , 2021, 10, e021276.	3.7	6
328	Biomarkers of Congestion. <i>JACC: Heart Failure</i> , 2020, 8, 398-400.	4.1	6
329	A bridge for the 21st century in heart transplantation?. <i>American Heart Journal</i> , 2003, 145, 198-199.	2.7	5
330	Management of the Cardiorenal Syndrome in Acute Heart Failure. Current Treatment Options in <i>Cardiovascular Medicine</i> , 2012, 14, 342-355.	0.9	5
331	Dysphagia in the Setting of Left Ventricular Assist Device Hemolysis. <i>ASAIO Journal</i> , 2013, 59, 322-323.	1.6	5
332	Is There a Rationale for Antiplatelet Therapy in Acute Heart Failure?. <i>Circulation: Heart Failure</i> , 2013, 6, 869-876.	3.9	5
333	CUPID 2: A Phase 2b Trial Investigating the Efficacy and Safety of the Intracoronary Administration of AAV1/SERCA2a in Patients with Advanced Heart Failure. <i>Journal of Cardiac Failure</i> , 2015, 21, 939-940.	1.7	5
334	Door-to-Furosemide Therapy in the ED. <i>Journal of the American College of Cardiology</i> , 2017, 69, 3052-3054.	2.8	5
335	Considering the duration of heart failure: using the past to predict the future. <i>European Journal of Heart Failure</i> , 2018, 20, 382-384.	7.1	5
336	Time Is Muscle in Acute Heart Failure. <i>JACC: Heart Failure</i> , 2018, 6, 295-297.	4.1	5
337	Must I keep taking all these medicines? Optimizing diuretics in chronic heart failure. <i>European Heart Journal</i> , 2019, 40, 3613-3615.	2.2	5
338	Physical Activity, Quality of Life, and Biomarkers in Atrial Fibrillation and Heart Failure With Preserved Ejection Fraction (from the NEAT-HFpEF Trial). <i>American Journal of Cardiology</i> , 2019, 123, 1660-1666.	1.6	5
339	Implications of peripheral oedema in heart failure with preserved ejection fraction: a heart failure network analysis. <i>ESC Heart Failure</i> , 2021, 8, 662-669.	3.1	5
340	Left ventricular assist devices as destination therapy for end-stage heart failure. <i>American Heart Journal</i> , 2004, 148, 252-253.	2.7	4
341	Reclassifying heart failure: time for disruptive innovation?. <i>European Journal of Heart Failure</i> , 2015, 17, 879-880.	7.1	4
342	Enrollment in Heart Failure Clinical Trials: Insights Into Which Entry Criteria Exclude Patients. <i>Journal of Cardiac Failure</i> , 2015, 21, 608-609.	1.7	4

#	ARTICLE	IF	CITATIONS
343	The Effect of Omecamtiv Mecarbil on Symptoms of Heart Failure in the Chronic Oral Study of Myosin Activation to Increase Contractility in Heart Failure (COSMIC-HF). <i>Journal of Cardiac Failure</i> , 2016, 22, S10-S11.	1.7	4
344	Clinical and Research Considerations for Patients With Hypertensive Acute Heart Failure: A Consensus Statement from the Society of Academic Emergency Medicine and the Heart Failure Society of America Acute Heart Failure Working Group. <i>Journal of Cardiac Failure</i> , 2016, 22, 618-627.	1.7	4
345	Comparison of Clinical Characteristics and Outcomes of Patients With Versus Without Diabetes Mellitus and With Versus Without Angina Pectoris (from the Duke Databank for Cardiovascular) Tj ETQq1 1 0.784314 rgBT /@overlock	1.7	4
346	Quantitative Blood Volume Analysis and Hemodynamic Measures of Vascular Compliance in Patients With Worsening Heart Failure. <i>Journal of Cardiac Failure</i> , 2022, 28, 1469-1474.	1.7	4
347	Changes in Dyspnea during Treatment of Acute Heart Failure Are Correlated with Clinical Signs, Rehospitalizations and Mortality. Results from the Pre-RELAX-AHF Trial. <i>Journal of Cardiac Failure</i> , 2009, 15, S62-S63.	1.7	3
348	Augmenting outcomes in patients with advanced heart failure. <i>European Heart Journal</i> , 2015, 36, 2276-2278.	2.2	3
349	Brain Natriuretic Peptide Treatment and Heart Failure Prevention. <i>JACC: Heart Failure</i> , 2016, 4, 548-550.	4.1	3
350	Inpatient Management of Heart Failure: Are We Shooting at the Right Target?. <i>Annals of Internal Medicine</i> , 2017, 166, 223.	3.9	3
351	Biomarkers for the Prevention of Heart Failure. <i>Journal of the American College of Cardiology</i> , 2018, 72, 3255-3258.	2.8	3
352	Biomarkers in Advanced Heart Failure. <i>Circulation: Heart Failure</i> , 2020, 13, e006840.	3.9	3
353	Improving In-Hospital Diuretic Therapy for Heart Failure. <i>Journal of the American College of Cardiology</i> , 2021, 77, 709-712.	2.8	3
354	Early diuretic strategies and the association with In-hospital and Post-discharge outcomes in acute heart failure. <i>American Heart Journal</i> , 2021, 239, 110-119.	2.7	3
355	The influence of comorbidities on achieving an Æterminal proÆbÆtype natriuretic peptide target: a secondary analysis of the GUIDEÆT trial. <i>ESC Heart Failure</i> , 2021, , .	3.1	3
356	Clinical trajectory of patients with a worsening heart failure event and reduced ventricular ejection fraction. <i>American Heart Journal</i> , 2022, 245, 110-116.	2.7	3
357	Topical Anesthesia With EMLA Reduces Pain During Endomyocardial Biopsy: a Randomized Trial. <i>Journal of Heart and Lung Transplantation</i> , 2006, 25, 1164-1166.	0.6	2
358	Too Much, Too Little, or Just Right?: Untangling Endogenous Erythropoietin in Heart Failure. <i>Circulation</i> , 2010, 121, 191-193.	1.6	2
359	Advanced Heart Failure. <i>Progress in Cardiovascular Diseases</i> , 2011, 54, 77.	3.1	2
360	Reply. <i>JACC: Heart Failure</i> , 2014, 2, 673.	4.1	2

#	ARTICLE	IF	CITATIONS
361	N-Terminal Pro-B-Type Natriuretic Peptide. Journal of the American College of Cardiology, 2014, 64, 1798-1800.	2.8	2
362	TIMING AND CLINICAL PREDICTORS OF EARLY VERSUS LATE READMISSION AMONG PATIENTS HOSPITALIZED FOR ACUTE HEART FAILURE: INSIGHTS FROM ASCEND-HF. Journal of the American College of Cardiology, 2017, 69, 766.	2.8	2
363	Site enrollment rate, outcomes, and study drug effects in a multicenter trial. Results from RELAX-AHF. International Journal of Cardiology, 2018, 253, 91-96.	1.7	2
364	Innovation in Diuretic Therapy. JACC Basic To Translational Science, 2018, 3, 35-37.	4.1	2
365	Haemoconcentration during treatment of acute heart failure with cardiorenal syndrome: from the CARRESS-HF trial. European Journal of Heart Failure, 2019, 21, 1472-1476.	7.1	2
366	Heart Failure as a Consequence of Ischemic Heart Disease. , 2020, , 254-268.e6.		2
367	Is Resistance Futile?. JACC: Heart Failure, 2020, 8, 169-171.	4.1	2
368	Comparative Effectiveness of Primary Prevention Implantable Cardioverter-Defibrillators in Older Heart Failure Patients With Diabetes Mellitus. Journal of the American Heart Association, 2020, 9, e012405.	3.7	2
369	The Impact of Depression on Outcomes in Patients With Heart Failure and Reduced Ejection Fraction Treated in the GUIDE-IT Trial. Journal of Cardiac Failure, 2021, 27, 1359-1366.	1.7	2
370	Cardiac transplantation at Duke University Medical Center. Clinical Transplants, 2004, , 235-41.	0.2	2
371	Using genetic information to select treatment for patients with heart failure: has the time come?. Personalized Medicine, 2009, 6, 385-392.	1.5	1
372	Plasma Renin Activity (PRA) Predicts Diuretic Resistance in Acute Heart Failure Patients: An Ancillary Study of the Diuretic Optimization Strategies Evaluation in Acute Heart Failure (DOSE-AHF). Journal of Cardiac Failure, 2011, 17, S25-S26.	1.7	1
373	Recurrence of heart failure symptoms after LVAD placement due to bradycardia-induced inflow obstruction. Journal of Heart and Lung Transplantation, 2012, 31, 111-113.	0.6	1
374	Hemodynamic Response to Continuous Outpatient Milrinone Infusion in Advanced Heart Failure Patients with Mixed Pulmonary Hypertension. Journal of Cardiac Failure, 2014, 20, S41.	1.7	1
375	Reply. Journal of the American College of Cardiology, 2015, 65, 1270-1271.	2.8	1
376	RATIONALE AND METHODS OF THE PROSPECTIVE STUDY OF BIOMARKERS, SYMPTOM IMPROVEMENT AND VENTRICULAR REMODELING DURING ENTRESTO THERAPY FOR HEART FAILURE (PROVE-HF) STUDY. Journal of the American College of Cardiology, 2017, 69, 711.	2.8	1
377	Heart Failure With Reduced Ejection Fraction in Human Immunodeficiency Virus Infection. JAMA Cardiology, 2017, 2, 476.	6.1	1
378	Combating Acute Heart Failure in the Arena. JACC: Heart Failure, 2018, 6, 871-873.	4.1	1

#	ARTICLE	IF	CITATIONS
379	EFFECT OF OMECAMTIV MECARBIL IN PATIENTS WITH ATRIAL FIBRILLATION AND HEART FAILURE WITH REDUCED EJECTION FRACTION: RESULTS FROM COSMIC-HF. <i>Journal of the American College of Cardiology</i> , 2019, 73, 691.	2.8	1
380	Challenges and Opportunities in the Evaluation of Nutraceuticals in Cardiovascular Diseases. <i>JACC Basic To Translational Science</i> , 2021, 6, 22-24.	4.1	1
381	Assessing race and ethnicity differences in outcomes based on GDMT and target NT-proBNP in patients with heart failure with reduced ejection fraction: An analysis of the GUIDE-IT study. <i>Progress in Cardiovascular Diseases</i> , 2022, , .	3.1	1
382	Plasma metabolites associated with functional and clinical outcomes in heart failure with reduced ejection fraction with and without type 2 diabetes. <i>Scientific Reports</i> , 2022, 12, .	3.3	1
383	The African-American heart failure trial: a new look at old drugs. <i>Future Cardiology</i> , 2005, 1, 311-313.	1.2	0
384	Dissociation of Patient and Physician Assessed Symptoms during Hospitalization for Acute Heart Failure: The Measure-HF Registry. <i>Journal of Cardiac Failure</i> , 2007, 13, S181.	1.7	0
385	Patient-Predicted Life Expectancy Among Ambulatory Patients With Heart Failure—Reply. <i>JAMA - Journal of the American Medical Association</i> , 2008, 300, 2116.	7.4	0
386	Admission, Discharge, or Change in BNP and Long-Term Mortality: Data from OPTIMIZE-HF Linked with Medicare Claims. <i>Journal of Cardiac Failure</i> , 2010, 16, S7-S8.	1.7	0
387	Response to Letter Regarding Article, “Mechanisms of Bleeding and Approach to Patients With Axial-Flow Left Ventricular Assist Devices” <i>Circulation: Heart Failure</i> , 2012, 5, .	3.9	0
388	PATIENT AND TRIAL FACTORS ASSOCIATED WITH NONPARTICIPATION IN RANDOMIZED CONTROLLED CARDIOVASCULAR TRIALS. <i>Journal of the American College of Cardiology</i> , 2012, 59, E1828.	2.8	0
389	Acute Decompensated Heart Failure. , 2014, , 166-171.		0
390	Clinical Characteristics and Outcomes of Patients with Discordant Findings at Right Heart Catheterization and Cardiopulmonary Exercise Testing. <i>Journal of Cardiac Failure</i> , 2014, 20, S49-S50.	1.7	0
391	The Clinical Implications of Cardiac Troponin I Measured by an “Ultrasensitive” Assay in Acute Decompensated Heart Failure: Insights from ASCEND-HF. <i>Journal of Cardiac Failure</i> , 2015, 21, S25-S26.	1.7	0
392	Reply. <i>Journal of the American College of Cardiology</i> , 2015, 66, 99.	2.8	0
393	Regional Differences during Acute Heart Failure Hospitalizations of Patients with Heart Failure with Preserved Ejection Fraction: Insights From ASCEND-HF. <i>Journal of Cardiac Failure</i> , 2016, 22, S27.	1.7	0
394	Improved Contractility and Evolution of Ventricular Remodelling Through Time in the Chronic Oral		

#	ARTICLE	IF	CITATIONS
397	Acute Decompensated Heart Failure. , 2018, , 233-240.		0
398	PROVIDER PERSPECTIVES ON THE FEASIBILITY AND UTILITY OF ROUTINE PATIENT-REPORTED OUTCOMES ASSESSMENT IN HEART FAILURE: A QUALITATIVE ANALYSIS. Journal of the American College of Cardiology, 2019, 73, 971.	2.8	0
399	Contemporary Medical Therapy for Heart Failure Patients with Reduced Ejection Fraction. , 2020, , 520-548.		0
400	Medications Are Important for Sudden Cardiac Death Prevention But So Is the Implantable Cardioverter-Defibrillator. JACC: Heart Failure, 2020, 8, 856-858.	4.1	0
401	A Biomarker Approach to UnderstandingÂHFpEF. Journal of the American College of Cardiology, 2020, 75, 1296-1298.	2.8	0
402	Setting the Stage for a Multimarker-Based HeartÂFailure Prevention Trial?. JACC: Heart Failure, 2021, 9, 224-225.	4.1	0
403	The lower is not always the better: a more comprehensive understanding of loop diuretics in heart failure. European Journal of Heart Failure, 2021, 23, 1120-1121.	7.1	0
404	Donâ€™t Be So Fast to Discard That Clean Catch!. JACC: Heart Failure, 2021, 9, 624-626.	4.1	0
405	Clinical Trial Design in Heart Failure. , 2010, , 570-593.		0
406	Acute Decompensated Heart Failure. , 2010, , 157-162.		0
407	Abstract 15556: Effects of Left Ventricular Assist Device Support on microRNA Levels. Circulation, 2014, 130, .	1.6	0
408	Leveraging Multiple Biomarkers to Assess Risk of Acute Heart Failure: Is More Better?. Journal of Cardiac Failure, 2022, 28, 234-236.	1.7	0
409	Natriuretic Peptides and Stratification for ICD Therapy in Nonischemic HeartÂFailure. JACC: Heart Failure, 2022, 10, 172-174.	4.1	0
410	Electronic-based Characterization And Outcomes Of Heart Failure With Preserved Ejection Fraction. Journal of Cardiac Failure, 2022, 28, S40-S41.	1.7	0